Pacira BioSciences Inc.
PCRX | NASDAQ
$24.68
+$0.57 (+2.36%)
Sep 22, 2026, 10:51 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 726.41M | 700.97M | 674.98M | 666.82M | 541.53M | 429.65M |
Cost of Revenue | 149.75M | 170.43M | 184.67M | 199.3M | 140.26M | 117.33M |
Gross Profit | 576.66M | 530.54M | 490.31M | 467.53M | 401.28M | 312.32M |
Operating Income | 33.3M | -73.37M | 87.68M | 60.02M | 89.92M | 46.35M |
Interest Income | 22.73M | 19.69M | 11.44M | 4.54M | 896K | 4.63M |
Pretax Income | 16.87M | -63.11M | 61.7M | 13.3M | 56.4M | 20.09M |
Net Income | 7.03M | -99.56M | 41.96M | 15.91M | 41.98M | 145.52M |
Selling & General & Admin | 368.76M | 294.1M | 269.44M | 254.52M | 199.35M | 193.52M |
Research & Development | 117.31M | 81.58M | 76.26M | 84.8M | 55.55M | 59.42M |
Other Expenses | 57.29M | 228.23M | 56.94M | 68.19M | 56.46M | 13.03M |
Operating Expenses | 543.36M | 603.91M | 402.63M | 407.5M | 311.35M | 265.97M |
Interest Expense | 14.61M | 16.57M | 17.31M | 35.58M | 29M | 25.67M |
Selling & Marketing Expenses | 226.62M | 172.02M | 153.04M | 145M | 111.02M | 118.68M |
Cost & Expenses | 693.11M | 774.34M | 587.3M | 606.8M | 451.61M | 383.3M |
Income Tax Expense | 9.84M | 36.45M | 19.75M | -2.61M | 14.42M | -125.43M |
Shares Outstanding (Basic) | 44.57M | 46.25M | 46.22M | 45.52M | 44.26M | 42.67M |
Shares Outstanding (Diluted) | 45.04M | 46.25M | 51.98M | 46.54M | 45.63M | 43.68M |
EPS (Basic) | 0.16 | -2.15 | 0.91 | 0.35 | 0.95 | 3.41 |
EPS (Diluted) | 0.16 | -2.15 | 0.89 | 0.34 | 0.92 | 3.33 |
EBITDA | 122.5M | 29.12M | 154.59M | 140.38M | 113.95M | 63.51M |
EBIT | 31.48M | -49.67M | 79.01M | 48.88M | 85.4M | 43.6M |
Depreciation & Amortization | 91.02M | 78.79M | 75.57M | 91.5M | 28.55M | 19.91M |
Add to Watchlist
Select watchlists to add or remove PCRX